Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS: Wistar Crl:WI rats
- Source:Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld
- Age at study initiation: 10 - 11 weeks
- Weight at study initiation: Males: 340 g – 395 g, Females: 230 g - 265 g
- Fasting period before study: overnight prior to treatment
- Housing: 5 animals of the same sex and group/cage with the exception of the mating and gestation/delivery period, when they
were paired or individually housed, respectively. (cage: Type II and/or III polycarbonate)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20,1-25
- Humidity (%): 36-70
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 20, 60, 200 mg/ml
- Amount of vehicle (if gavage): 5 mL/kg bw
According to the results of a stability study, the test material was stable in Propylene glycol in concentration range of 20-200 mg/mL for 24 hours at room temperature (RT, 15-30ºC) and for up to three days when stored refrigerated at 2-8ºC (protected from light) and the homogeneity of the formulations was satisfactory. - Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: for up to 6 days
- After successful mating each pregnant female was caged individually
- Mating of siblings was avoided. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of WS400102 formulations for concentration and homogeneity was performed using validated HPLC-UV method (CiToxLAB study code 11/350-316AN). The concentration analysis was performed on 3 occasions, during the first, fourth and last weeks of the treatment period. Recovery of WS400102 from propylene glycol was in the range from 97 to 105%.
- Duration of treatment / exposure:
- Main males: 35 days (14 days pre-mating, 14 days mating/post-mating period followed by an additional week)
Main females: ca. 47 days (14 days pre-mating, for up to 7 days mating period, through gestation til PPD 4)
[Satellite females (nulliparous and nonpregnant): 35 days] - Frequency of treatment:
- daily, 7 days/week
- Details on study schedule:
- - Age at mating of the mated animals in the study: 12-13 weeks
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Main groups: 12 animals/sex/dose
[Satellite group (20 femal rats): 5 animals/dose]
Offspring were not dosed. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Based on available data and information from previous experimental work, including the results of a preliminary dose range finding study in the rat (Endpoint study report 7.5.1 Dose Range Finding Study 7 days rat_WS400102) , the dose levels selected for this study were 100, 300 and 1000 mg/kg bw/day.
This study was conducted to examine both repeated dose toxicity and reproductive/developmental toxicity as an OECD screening combined study (OECD 422 test guideline). Therefore, animals initially entering the study were divided into toxicity subgroup animals (Satellite females) and reproductive subgroup animals (Main females and males), whereby 5 of the 12 Main males (used for pairing) per dose group formed the toxicity male Subgroup A. - Positive control:
- No
- Parental animals: Observations and examinations:
- CAGE SIDE OBSERVATIONS
- Time schedule: twice daily
All animals were monitored for pertinent behavioural changes, signs of difficult or prolonged parturition and all signs of toxicity including mortality.
Delivery process was observed as carefully as possible. Dams were observed to record whether they form a nest from the bedding material and cover their new-borns or not.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least weekly (observations in a standard arena)
BODY WEIGHT: Yes
- Time schedule: Parent females were weighed on gestation Days GD 0, 7, 14 and 20 and on postpartal Days PPD0 (within 24 hours after parturition), and PPD5 (before termination).
Parent males were weighed on Day 0 and at least weekly. - Sperm parameters (parental animals):
- Parameters examined in male parental generations, all males (12/dose):
testes, epididymides (total and cauda), prostate, seminal vesicles with coagulating glands.
Special attention was paid to evaluation of the stages of spermatogenesis in the male gonads and histopathology of interstitial testicular cell structure. - Litter observations:
- STANDARDISATION OF LITTERS Not performed. The study ended on Lactation Day 4.
The following parameters were examined in F1- offspring:
number and sex of pups, stillbirths, live births; postnatal mortality; presence of gross anomalies, weight gain (PPD0-PPD4), physical or behavioural abnormalities
GROSS EXAMINATION OF DEAD PUPS:
yes; for external abnormalities, any pups showing abnormalities in structure or behaviour were subjected to necropsy with macroscopic examination. - Postmortem examinations (parental animals):
- SACRIFICE
- Male animals: All surviving animals on Day 35.
- Maternal animals: All surviving animals on Day 5 of lactation (PND5).
GROSS NECROPSY
- Gross necropsy consisted of external examinations including the cervical, thoracic, and abdominal viscera.
- Special attention was paid to the organs of the reproductive system. The number of implantation sites and of corpora lutea were recorded in the Main females as applicable.
ORGAN WEIGHTS
Weight of the following organs of all adult animals were determined:
- With a precision of 0.01 g: uterus (with and without cervix), vagina, testes, epididymides (total and cauda), prostate, seminal vesicles with coagulating glands, brain
- With a precision of 0.001 g: ovaries, pituitary
HISTOPATHOLOGY :
Detailed histological examinations was performed in all main adults of control and high dose groups.
Special attention was paid to evaluation of the stages of spermatogenesis in the male gonads and histopathology of interstitial testicular cell structure.
Detailed histological examination of the ovaries covered the follicular, luteal, and interstitial compartments of the ovary, as well as the epithelial capsule and ovarian stroma. - Postmortem examinations (offspring):
- SACRIFICE
- The F1 offspring on Day 4:
Pups were carefully examined at least externally for gross abnormalities. Any pups showing abnormalities in structure or behaviour were subjected to necropsy with macroscopic examination. The probable cause of death of dead pups were recorded if it can be identified, e.g. cannabilism.
Macroscopic examination included assessment of the presence of milk in the stomach, where possible. - Statistics:
- The statistical evaluation of appropriate data (marked † below) was performed with the statistical program package SPSS PC+4.0. The homogeneity of variance between groups was checked by Bartlett’s homogeneity of variance test. Where no significant heterogeneity was detected, a one-way analysis of variance (ANOVA) was carried out. If the obtained result was significant, Duncan Multiple Range test was used to access the significance of inter-group differences. Getting significant result at Bartlett’s test, the Kruskal-Wallis analysis of variance was used and the inter-group comparisons were performed using Mann-Whitney U-test. Chi2 test was performed as feasible.
- Reproductive indices:
- Formulas for Calculation of Mating and Fertility Indices
Male Mating Index: Number of males with confirmed mating : Total Number of males cohabited x 100
Female Mating Index: Number of sperm-positive females : Total Number of females cohabited x 100
Male Fertility Index: Number of males impregnating a female : Total Number of males cohabited x 100
Female Fertility Index: Number of pregnant females : Number of sperm-positive females x 100
Gestation Index: Number of females with live born pups : Number of pregnant females x 100 - Offspring viability indices:
- Formulas for Calculation of Pups’ Mortality and Sex Ratio Indices
Survival Index: Number of live pups (at designated time) : Number of pups born x 100
Pre-implantation mortality: (Number of Corpora lutea − Number of Implantations) : Number of Corpora lutea x 100
Intrauterine mortality: (Number of implantations - Number of liveborns) : Number of implantations x 100
Total mortality: (Number of implantations - Number of viable pups (d4)) : Number of implantations x 100
Post-natal mortality: (Number of viable pups (d0) - Number of viable pups (d4)) : Number of viable pups (d0) x 100
Sex ratio: (Number of pups exa min ed − Number of males) : Number of pups examined x 100 - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Findings noted in the liver of males at 1000 mg/kg bw/day (High dose). Slight effects in kidneys of females.
- Other effects:
- no effects observed
- Reproductive function: oestrous cycle:
- no effects observed
- Reproductive function: sperm measures:
- no effects observed
- Reproductive performance:
- effects observed, treatment-related
- Description (incidence and severity):
- see Table on Reproductive Performance attached in attached background material
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 300 - <= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- System:
- other: slight changes in haematology, clinical chemistry, kidney (females only), liver (males only) in high dose animals
- Organ:
- kidney
- liver
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- not specified
- Clinical signs:
- no effects observed
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- see Tables on F1 generations attached in attached background material
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- see Table on body weight of F1 generation attached in attached background material
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- not examined
- Description (incidence and severity):
- No abnormalities were observed at external examination.
- Histopathological findings:
- not examined
- Other effects:
- no effects observed
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: NOAEL = highest dose tested, administered to the parental animals, offspring were not dosed, F1 observations up to 4 days of age.
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- In conclusion, in this study - OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test) - daily oral gavage administration of WS400102 to Wistar rats at dose levels of 100, 300 and 1000 mg/kg bw/day was associated with week signs of reproduction toxicity in the High dose group and the NOAEL was considered to be 300 mg/kg bw/day. These effects were considered to be secondary to parental toxicity.
Reference
There was no mortality during the study.
There were no clinical signs related to treatment.
BODY WEIGHT AND FOOD CONSUMPTION (PARENTAL ANIMALS)
There was no adverse effect of test material on body weight or body weight gain. Body weights were comparable to the control in all treated groups.
There was no adverse effect of treatment on food consumption.
REPRODUCTIVE PERFORMANCE (PARENTAL ANIMALS)
There was no effect of treatment on the oestrus cycle or reproductive parameters.There were no differences between the Control and test material-treated groups with regard to reproductive ability or in the mating or gestation indices, or effects considered adverse or toxicologically significant in correlation with WS400102 administration.
The mating indices were 100% in all groups, while fertility indices were 92% in control and Mid groups, 83% in Low group and 75% in High dose animals.
There is no statistical difference to control, but a relationship with treatment cannot be excluded. Any differences are considered to be probably related to maternal toxicity.
WS400102 was considered to have no impact on the duration of the mating period. Successful coitus generally occurred within up to 6 days of pairing.
The mean duration of pregnancy was similar in the control and test material treated groups and varied between 22 and 23 days. The differences were considered as individual animal variation.
The gestation index was 100% in control, Low and Mid groups and 89% at 1000 mg/kg bw/day (High dose). In the High dose group, the slightly lower gestation index value was due to one female, pregnant with two implantation sites but not delivered. However, values are comparable with concurrent control data in Wistar rats. (see Table 1 "Any other information on results incl. tables")
All the parturitions were normal.
Slightly increased pre-implantation, total intrauterine and postnatal mortality values in the High dose group were observed.These small differences were considered to be probably secondary to maternal toxicity.
ORGAN WEIGHTS, GROSS PATHOLOGY, HISTOPATHOLOGY (PARENTAL ANIMALS)
Animals had slightly increased liver weights (by approximately 23-26% in males and 16-19% in females) accompanied by a minimal/mild changes in males in the form of diffuse hepatocellular vacuolation of all lobes (6/9 males) and centrilobular hypertrophy (4/9 males).
Females had histological minimal changes in kidneys in the form of bilateral vacuolation and presence of cytoplasmic eosinophilic granules in the cortical tubules (2/5 females).
No test material-related microscopic changes were noted in the reproductive organs at a dose level of 1000 mg/kg bw. Histopathological evaluation of the male gonads as well as testicular interstitial cell structure, the spermatogenic cells representing different phases of the development and differentiation of the spermatozoons were similar in Control and High Dose males. The follicular, luteal and interstitial compartments of the ovary as well as epithelial capsule and stroma were similar histological structure in both Control and High Dose females.
Randomly distributed changes across control and treated groups were regarded as incidental or common background.
WS400102 administered to parental generation at up to 1000 mg/kg bw/day did not lead to mortality or any adverse effects considered related to treatment or toxicologically significant in the F1 generation. No abnormal behaviour of the pups was noted. No external abnormalities ascribed to treatment were detected at the clinical or external macroscopic examinations of the pups.
The number of viable pups on PND4 was slightly lower at 1000 mg/kg bw/day, when compared to control (p<0.05), which was in accordance with slightly lower number of live-born pups noted on PND0.
The survival indices of pups on PND0 and PND4 were comparable to control values at up to and including 1000 mg/kg bw/day. The incidence of mortality was negligible.
The sex ratios were similar in the Control and treated groups.
BODY WEIGHT (OFFSPRING)
There was no adverse effect of treatment on the offspring body weight or body weight gain.
Mean body weights values evaluated for all pups or on litter basis were similar in all treated groups.
Compared to control, slightly lower mean overall body weight gain values (PND0-4) were noted at 1000 mg/kg. The differences were in the range of 5% (litter basis) and 7% (all pups) and the differences attained statistical significance for all pups basis (p<0.05).
GROSS PATHOLOGY
No abnormalities in structure or behaviour were noted, therefore no necropsy with macroscopic examination was necessary.
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 300 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The reproduction toxicity screening test is adequate for an initial assessment of effects on fertility; it is of high quality and reliability.
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
The UVCB substance WS400102 to the biggest part is a physical mixture / salt of tall oil fatty acids and (technical) triethanolamine (TEA); only a small portion reacts forming monoesters. The technical quality of TEA contains up to 15% diethanolamine (DEA). DEA is known for its toxicity towards haematological parameters, liver and kidney in rats (Melnick et al, 1994). A NOAEL for haematological changes could not be derived in this study. The LOAEL after 90 day oral exposure amounted to 15 mg and 25 mg/kg body weight/day in females and males, respectively.
The highest dose applied in the combined repeated dose toxicity study with reproduction / developmental toxicity screening was 1000 mg/kg/day. This dose of WS400102 corresponds to up to 50 mg DEA/kg body weight/day according to the chemical composition of the UVCB substance. The effects observed in the parental animals of the high dose group after 35 days of exposure to WS400102 focused on changes in haematology, clinical chemistry parameters as well as slight effects in liver and kidney. These effects qualitatively and quantitatively correlated well with the effects observed in the 90 day study with DEA. Thus, it is very likely that the slight effects observed in the present study on reproductive parameters in high dose females are due to the toxicity of DEA.
DEA is classified (Regulation 1272/2008) STOT RE2 for specific organ toxicity next to acute toxicity, i.e. oral (cat. 4), skin irritation, eye damage, but not for reproduction toxicity. The other two substances used in the manufacture of WS400102, i.e. TEA and tall oil fatty acids, are not classified at all. Also esters that may be formed at low levels during manufacture of WS400102 are not toxic to reproduction as was shown for another substance produced from the same starting materials (CAS 67784 -78 -5).
In sum, there is no need for classification of WS400102 for reproductive toxicity.
Melnick, R.L., Mahler, J., Bucher, J.R., Thompson, M., Hejtmancik, M., Ryan, M.J., and Mezza, L.E. (1994): Toxicity of diethanolamine. 1. Drinking water and topical application exposures in F344 rats. In: J. Appl. Toxicol. 14, pp. 1 – 9.
Short description of key information:
In the Combined Repeated Dose Toxicity Study with the
Reproduction/Developmental Toxicity Screening Test (OECD 422) next to
the parameters determined to examine toxicological effects in general,
the reproductive performance and indices were monitored in the adult
main animals, such as gonadal function, mating behaviour, conception,
pregnancy, parturition and postpartum/lactation period.
Results: There was no effect of treatment on the oestrus cycle or
reproductive parameters like reproductive ability, mating period,
gestation and fertility indices as well as on parturition and
post-partal period. Slightly increased pre-implantation, total
intrauterine and postnatal mortality values and slightly lower number of
born pups as well as slightly lower body weight gain of pups were
observed in animals of the high dose group (1000 mg/kg/day). These
small, statistically not significant differences were considered to be
probably secondary to maternal toxicity.
Justification for selection of Effect on fertility via oral route:
Well performed screening study. The slight effects observed are
considered secondary to maternal toxicity and not indicative of
reproductive toxicity.
Effects on developmental toxicity
Description of key information
The Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test (OECD 422) included a development toxicity-screening test, intended to provide information on possible effects on the development of the F1 offspring from conception to Day 4 post-partum.
Offspring examinations: clinical signs, body weight, body weight gain, number of live births and of viable pups per litter on postnatal Days 0 and 4, sex ratio.
Results: Adverse effects on the maternal (and male) animals in the high dose group included changes in haematology and clinical chemistry parameters. Slightly increased liver weights, histological minimal changes in kidneys (females only) were observed.
There were no adverse effects on the F1 offspring viability, clinical signs or development.
Link to relevant study records
- Endpoint:
- developmental toxicity
- Remarks:
- from OECD 422 study with reproduction / developmental toxicity screening
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
- Qualifier:
- according to guideline
- Guideline:
- other: OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS: Wistar Crl:WI rats
- Source:Charles River Laboratories, Research Models and Services, Germany GmbH, Sandhofer Weg 7, D-97633 Sulzfeld
- Age at study initiation: 10 - 11 weeks
- Weight at study initiation: Males: 340 g – 395 g, Females: 230 g - 265 g
- Fasting period before study: overnight prior to treatment
- Housing: 5 animals of the same sex and group/cage with the exception of the mating and gestation/delivery period, when they
were paired or individually housed, respectively. (cage: Type II and/or III polycarbonate)
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 6 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20,1-25
- Humidity (%): 36-70
- Air changes (per hr): 15-20
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- VEHICLE
- Concentration in vehicle: 20, 60, 200 mg/ml
- Amount of vehicle (if gavage): 5 mL/kg bw
According to the results of a stability study, the test material was stable in Propylene glycol in concentration range of 20-200 mg/mL for 24 hours at room temperature (RT, 15-30ºC) and for up to three days when stored refrigerated at 2-8ºC (protected from light) and the homogeneity of the formulations was satisfactory - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of WS400102 formulations for concentration and homogeneity was performed using validated HPLC-UV method (CiToxLAB study code 11/350-316AN). The concentration analysis was performed on 3 occasions, during the first, fourth and last weeks of the treatment period. Recovery of WS400102 from propylene glycol was in the range from 97 to 105%.
- Details on mating procedure:
- - M/F ratio per cage: 1:1
- Length of cohabitation: for up to 6 days
- After successful mating each pregnant female was caged individually
- Mating of siblings was avoided. - Duration of treatment / exposure:
- Main males: 35 days (14 days pre-mating, 14 days mating/post-mating period followed by an additional week)
Main females: ca. 47 days (14 days pre-mating, for up to 7 days mating period, through gestation til PPD 4)
[Satellite females (nulliparous and nonpregnant): 35 days] - Frequency of treatment:
- daily, 7 days/week
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- No. of animals per sex per dose:
- Main groups: 12 animals/sex/dose
[Satellite group (20 femal rats): 5 animals/dose]
Offspring were not dosed. - Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale:
Based on available data and information from previous experimental work, including the results of a preliminary dose range finding study in the rat (Endpoint study report 7.5.1 Dose Range Finding Study 7 days rat_WS400102) , the dose levels selected for this study were 100, 300 and 1000 mg/kg bw/day.
This study was conducted to examine both repeated dose toxicity and reproductive/developmental toxicity as an OECD screening combined study (OECD 422 test guideline). Therefore, animals initially entering the study were divided into toxicity subgroup animals (Satellite females) and reproductive subgroup animals (Main females and males), whereby 5 of the 12 Main males (used for pairing) per dose group formed the toxicity male Subgroup A. - Maternal examinations:
- CAGE SIDE OBSERVATIONS
- Time schedule: twice daily
All animals were monitored for pertinent behavioural changes, signs of difficult or prolonged parturition and all signs of toxicity including mortality.
Delivery process was observed as carefully as possible. Dams were observed to record whether they form a nest from the bedding material and cover their new-borns or not.
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least weekly (observations in a standard arena)
BODY WEIGHT: Yes
- Time schedule: Maternal animals were weighed on gestation Days GD 0, 7, 14 and 20 and on postpartal Days PPD0 (within 24 hours after parturition), and PPD5 (before termination).
POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on Day 5 of lactation (PND5)
- Organs examined: uterus, vagina, ovaries
HISTOPATHOLOGY :
Detailed histological examinations was performed in all maternal animals of control and high dose groups of the ovaries covered the follicular, luteal, and interstitial compartments of the ovary, as well as the epithelial capsule and ovarian stroma. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes (with and wtihout cervix)
- Number of corpora lutea: Yes
- Number of implantations: Yes
Post implantation survival was determined.
In addition, gestation length (time elapsing between detection of mating and commencement of parturition) was recorded. - Fetal examinations:
- - External examinations: from PPD0 to PPD4, all pubs per litter
parameters observed: number and sex of pups, stillbirths, live births; postnatal mortality; presence of gross anomalies, weight gain (PPD0-PPD4), physical or behavioural abnormalities - Statistics:
- The statistical evaluation of appropriate data (marked † below) was performed with the statistical program package SPSS PC+4.0. The homogeneity of variance between groups was checked by Bartlett’s homogeneity of variance test. Where no significant heterogeneity was detected, a one-way analysis of variance (ANOVA) was carried out. If the obtained result was significant, Duncan Multiple Range test was used to access the significance of inter-group differences. Getting significant result at Bartlett’s test, the Kruskal-Wallis analysis of variance was used and the inter-group comparisons were performed using Mann-Whitney U-test. Chi2 test was performed as feasible.
- Indices:
- Female Mating Index: Number of sperm-positive females : Total Number of females cohabited x 100
Female Fertility Index: Number of pregnant females : Number of sperm-positive females x 100
Gestation Index: Number of females with live born pups : Number of pregnant females x 100
Formulas for Calculation of Pups’ Mortality and Sex Ratio Indices
Survival Index: Number of live pups (at designated time) : Number of pups born x 100
Pre-implantation mortality: (Number of Corpora lutea − Number of Implantations) : Number of Corpora lutea x 100
Intrauterine mortality: (Number of implantations - Number of liveborns) : Number of implantations x 100
Total mortality: (Number of implantations - Number of viable pups (d4)) : Number of implantations x 100
Post-natal mortality: (Number of viable pups (d0) - Number of viable pups (d4)) : Number of viable pups (d0) x 100
Sex ratio: (Number of pups exa min ed − Number of males) : Number of pups examined x 100 - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Behaviour (functional findings):
- no effects observed
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- in high dose females of the OECD 422 study microscopic findings were observed in kidney
- Number of abortions:
- no effects observed
- Pre- and post-implantation loss:
- effects observed, non-treatment-related
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Total litter losses by resorption:
- no effects observed
- Early or late resorptions:
- effects observed, non-treatment-related
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Dead fetuses:
- effects observed, non-treatment-related
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Changes in pregnancy duration:
- no effects observed
- Changes in number of pregnant:
- effects observed, non-treatment-related
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Other effects:
- no effects observed
- Details on maternal toxic effects:
- Maternal toxic effects:yes. Remark: In High dose group: changes in haematology, in some parameters of clinical chemistry, slightly increased liver weight, histological minimal changes in kidneys
Details on maternal toxic effects:
In the High dose group (1000 mg): Changes in haematology (decrease of 8-12% in erythrocyte count, hemoglobin concentration and hematocrit value) and clinical chemistry parameters (increase in albumin concentration and albumin to globulin ration, higher calcium, sodium and chloride concentrations). Animals had slightly increased liver weights (16-19%) changes. Females had histological minimal changes in kidneys in the form of bilateral vacuolation and presence of cytoplasmic eosinophilic granules in the cortical tubules (2/5 females).
Slightly increased pre-implantation, total intrauterine and postnatal mortality values and slightly lower number of born pups as well as slightly lower body weight gain of pups were observed. These small differences were considered to be probably secondary to maternal toxicity. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: developmental toxicity
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 300 - <= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Basis for effect level:
- other: maternal toxicity
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Reduction in number of live offspring:
- no effects observed
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Changes in sex ratio:
- no effects observed
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Changes in litter size and weights:
- no effects observed
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Changes in postnatal survival:
- no effects observed
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- External malformations:
- no effects observed
- Description (incidence and severity):
- see Tables on F1 generation attached in attached background material
- Skeletal malformations:
- not examined
- Visceral malformations:
- not examined
- Other effects:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- Embryotoxic / teratogenic effects:no effects
Details on embryotoxic / teratogenic effects:
No external abnormalities ascribed to treatment were detected at the clinical or external macroscopic examinations of the pups. At 300 mg/kg in one male pup aplasia of the tail was detected without any internal abnormality. The incidence of this finding was low, within the physiological range expected in the population of Wistar rats and considered without toxicological significance, or to reflect a test item or adverse effect.
The survival indices of pups on PND0 and PND4 were comparable to control values at up to and including 1000 mg/kg bw/day. The incidence of mortality was negligible and was 1 of 160 in control, 1 of 156 in Low dose, 6 of 155 in Mid dose and 3 of 89 in High dose. Three of 6 dead pups in the Mid dose and 3 of 3 dead pups in the High dose originated from one litter. All of these pups were lost on Day PND1, except one pup of Mid dose (PND4) and control (PND2). These pups were probably cannibalized.The sex ratios were similar in the Control and treated groups.
There was no adverse effect of treatment on the offspring body weight or body weight gain. Slightly higher mean body weights values in the Low dose group and slightly lower mean overall body weight gain values (PND0-4) in the High dose group were regarded as individual, biological variability, without
toxicological significance. - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Key result
- Abnormalities:
- no effects observed
- Key result
- Developmental effects observed:
- no
- Conclusions:
- WS400102 administered to parental generation at up to 1000 mg/kg bw/day did not lead to mortality or any adverse effects considered related to treatment or toxicologically significant in the F1 generation.
Reference
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
- Quality of whole database:
- The development toxicity screening test is is adequate for an initial assessment of effects on development toxicity; it is of high quality and reliability.
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Following the results of the available studies classification of WS400102 regarding reproductive or developmental toxicity is not warranted according to European classification rules [ REGULATION (EC) 1272/2008].
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.